Navigation Links
Drug shows promise for the first time against metastatic melanoma of the eye
Date:6/19/2014

NEW YORK, NY (June 19, 2014) For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

Results from a multicenter clinical trial show that a new drug called selumetinib increases progression-free survival, the length of time during and after treatment that a patient with metastases lives with the disease without it progressing. The findings were published today in the online edition of JAMA, the Journal of the American Medical Association.

"Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development," said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center. (At the time of the trial, Dr. Schwartz was chief of the melanoma and sarcoma service at Memorial Sloan Kettering Cancer Center in New York.)

Uveal melanoma is a cancer of the iris, ciliary body, or choroidstructures in the eye collectively known as the uvea. Uveal melanoma (which is biologically distinct from skin melanoma) arises from the uvea's melanocytes, the pigment cells that give the eye its color. Once the disease has spreadmost metastases appear in the liverexisting treatments are largely ineffective. About 1,500 cases of uveal melanoma occur in the United States each year, usually among older adults. The median survival rate for patients with metastatic uveal melanoma is 12 months.

Several years ago, researchers found that 80 percent of patients with uveal melanoma had mutations to GNAQ or GNA11, genes that activate signals in the mitogen-activated protein kinase (MAPK) pathway. Dr. Schwartz and others subsequently demonstrated that inhibition of MEK, a key enzyme in the MAPK pathway, can inhibit the growth of uveal melanoma cells in the laboratory. Dr. Schwartz's laboratory was the first to show this with selumetinib.

In 2013, Dr. Schwartz and his colleagues launched the first large-scale, Phase II, randomized trial of selumetinib. One hundred and one patients with metastatic uveal melanoma at 15 centers in the United States and Canada were randomized to receive either selumetinib or standard chemotherapy. Those in the chemotherapy group could receive selumetinib at any time if they showed signs of disease progression.

Median progression-free survival among patients receiving selumetinib was more than double that of patients receiving chemotherapy (15.9 weeks vs. 7 weeks). Forty-nine percent of patients treated with selumetinib exhibited tumor regression, compared with none in the chemotherapy group.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant. "We suspect that there may have been improvement in survival in the selumetinib group, but it was unclear, because patients who didn't respond to chemotherapy were allowed to cross over to selumetinib," said Dr. Schwartz. "That's something we hope to clarify in a follow-up study that is now under way."

The vast majority of patients taking selumetinib experienced side effects, including rash, swelling, and visual changes. Most of the side effects were considered manageable, although 37 percent of patients required at least one dose reduction and 6 percent discontinued therapy.

Dr. Schwartz thinks that treatment of uveal melanoma will ultimately involve rational drug design and a combination of drugs, similar to the approach used to combat HIV infection. "In preclinical studies, we've shown that when a MEK inhibitor was combined with an Akt inhibitor, which affects another cancer-related pathway, the results were better than when using MEK alone," he said.

"Overall," Dr. Schwartz added, "the study underscores the importance of rational drug design, in which drugs are designed to interact with specific molecular pathways involved in a particular disease. This is a huge improvement over chemotherapy, which is basically a blanket approach to cancer that does not directly address the underlying biology."


'/>"/>

Contact: Karin Eskenazi
Ket2116@columbia.edu
Columbia University Medical Center
Source:Eurekalert  

Related biology news :

1. BU-lead study shows surprising spread of spring leaf-out times
2. Study shows race a factor in mortality in heart attack patients on anti-clotting drug
3. Arctic warming linked to fewer European and US cold weather extremes, new study shows
4. New study shows that oatmeal can help you feel full longer
5. Saving trees in tropics could cut emissions by one-fifth, study shows
6. Doing more means changing less when it comes to gene response, new study shows
7. Research shows compassion and euthanasia dont always jibe
8. Study shows impact of tart cherries on inflammation and oxidative stress after cycling
9. Marijuana shows potential in treating autoimmune disease
10. Study shows tale of 2 prognoses in pediatric brain tumor, pilocytic astrocytoma
11. ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug shows promise for the first time against metastatic melanoma of the eye
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
Breaking Biology News(10 mins):
(Date:5/16/2017)... , ... (PRWEB) May 16, ... ... Congress of the Chinese Association of Orthopaedic Surgeons (CAOS), long-standing development partners ... collaborated on an interbody spine surgery workshop to help expand knowledge of ...
(Date:5/15/2017)... of Prussia, PA (PRWEB) , ... May 15, 2017 , ... ... sharing her insights in a presentation of “The Key Role of Specifications in Process ... Racquet Club of Philadelphia . The event will bring together leaders from the pharmaceutical ...
(Date:5/15/2017)... ... May 15, 2017 , ... Algenist ... Lift Contouring Cream, a gravity-shattering cream with a patented formula, clinically proven to ... bring the Advanced Lift Contouring Cream to our already innovative ELEVATE product line,” ...
(Date:5/15/2017)... N.Y. , May 15, 2017  IBM (NYSE: ... technology that can stretch double-stranded DNA molecules with ... indicate disease. This technology complements the ... separates bioparticles, such as exosomes and which may ... technology, which uses an array of diamond shaped ...
Breaking Biology Technology: